Product
JYP0322
1 clinical trial
4 indications
Indication
Protein Kinase InhibitorsIndication
Other Protocol Specified CriteriaIndication
Lung CancerIndication
Brain NeoplasmsClinical trial
A Phase 1 Study of Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JYP0322 in Patients With Locally Advanced/Metastatic Solid Tumors Harboring ROS1 Gene FusionStatus: Recruiting, Estimated PCD: 2024-06-30